

## Supplementary materials

Supplementary Table 1. Objective Response Rate for Subgroups Defined by Age

Age	IRC-assessed		Investigator-assessed	
	< 65 years (n = 97)	≥ 65 years (n = 8)	< 65 years (n = 97)	≥ 65 years (n = 8)
<b>Best overall response, n (%)</b>				
Complete response	6 (6.2)	0	3 (3.1)	1 (12.5)
Partial response	21 (21.6)	2 (25.0)	21 (21.6)	2 (25.0)
Stable disease	27 (27.8)	2 (25.0)	32 (33.0)	1 (12.5)
Progressive disease	33 (38.1)	2 (25.0)	36 (37.1)	2 (25.0)
Unable to evaluate	4 (4.8)	2 (25.0)	5 (5.2)	2 (25.0)
<b>Objective response rate, n (%)</b>	27 (27.8)	2 (25.0)	24 (24.7)	3 (37.5)
95% CI* (%)	19.21-37.86	3.19-65.09	16.54-34.54	8.52-75.51
<i>P</i> value**	<0.0001	0.1869	<0.0001	0.0381

\*95% CIs were estimated using the Clopper-Pearson exact test. \*\*Binomial exact test assuming that the ORR of a historical control monotherapy was 10%. CI, confidence interval; IRC, independent review committee.

**Supplementary Table 2.** Objective Response Rate for Subgroups Defined by ECOG Performance Status

ECOG performance status	IRC-assessed		Investigator-assessed	
	PS 0 (n = 38)	PS 1 (n = 67)	PS 0 (n = 38)	PS 1 (n = 67)
<b>Best overall response, n (%)</b>				
Complete response	3 (7.9)	3 (4.5)	0	4 (6.0)
Partial response	11 (28.9)	12 (17.9)	13 (34.2)	10 (14.9)
Stable disease	9 (23.7)	20 (29.9)	12 (31.6)	21 (31.3)
Progressive disease	15 (39.5)	24 (35.8)	13 (34.2)	25 (37.3)
Unable to evaluate	0	8 (11.9)	0	7 (10.4)
<b>Objective response rate, n (%)</b>	14 (36.8)	15 (22.4)	13 (34.2)	14 (20.9)
95% CI* (%)	21.81-54.01	13.11-34.22	19.63-51.35	11.92-32.57
<i>P</i> value**	<0.0001	0.0022	<0.0001	0.0059

\*95% CIs were estimated using the Clopper-Pearson exact test. \*\*Binomial exact test assuming that the ORR of a historical control monotherapy was 10%. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee.

**Supplementary Table 3.** Objective Response Rate for Subgroups Defined by PD-L1 Expression

PD-L1 expression	IRC-assessed		Investigator-assessed	
	1 to < 20 (n = 66)	≥ 20 (n = 39)	1 to < 20 (n = 66)	≥ 20 (n = 39)
<b>Best overall response, n (%)</b>				
Complete response	3 (4.5)	3 (7.7)	1 (1.5)	3 (7.7)
Partial response	9 (13.6)	14 (35.9)	10 (15.2)	13 (33.3)
Stable disease	17 (25.8)	12 (30.8)	17 (25.8)	16 (41.0)
Progressive disease	31 (47.0)	8 (20.5)	33 (50.0)	5 (12.8)
Unable to evaluate	6 (9.1)	2 (5.1)	5 (7.6)	2 (5.1)
<b>Objective response rate, n (%)</b>	12 (18.2)	17 (43.6)	11 (16.7)	16 (41.0)
95% CI* (%)	9.76-29.61	27.81-60.38	8.62-27.87	25.57-57.90
<i>P</i> value**	0.0295	<0.0001	0.0621	<0.0001

\*95% CIs were estimated using the Clopper-Pearson exact test. \*\*Binomial exact test assuming that the ORR of a historical control monotherapy was 10%. CI, confidence interval; IRC, independent review committee; PD-L1, programmed death ligand-1.

**Supplementary Table 4.** Objective Response Rate for Subgroups Defined by Previous Lines of Treatment

Number of previous lines of treatment	IRC-assessed			Investigator-assessed		
	1 (n = 64)	2 (n = 32)	≥ 3 (n = 9)	1 (n = 64)	2 (n = 32)	≥ 3 (n = 9)
<b>Best overall response, n (%)</b>						
Complete response	3 (4.7)	1 (3.1)	2 (22.2)	3 (4.7)	0	1 (11.1)
Partial response	16 (25.0)	6 (18.8)	1 (11.1)	14 (21.9)	7 (21.9)	2 (22.2)
Stable disease	17 (26.6)	8 (25.0)	4 (44.4)	17 (26.6)	12 (37.5)	4 (44.4)
Progressive disease	21 (32.8)	16 (50.0)	2 (22.2)	24 (37.5)	12 (37.5)	2 (22.2)
Unable to evaluate	7 (10.9)	1 (3.1)	0	6 (9.4)	1 (3.1)	0
<b>Objective response rate, n (%)</b>	19 (29.7)	7 (21.9)	3 (33.3)	17 (26.6)	7 (21.9)	3 (33.3)
95% CI* (%)	18.91-42.42	9.28-39.97	7.49-70.07	16.30-39.09	9.28-39.97	7.49-70.07
<i>P</i> value**	<0.0001	0.0358	0.0530	0.0001	0.0358	0.0530

\*95% CIs were estimated using the Clopper-Pearson exact test. \*\*Binomial exact test assuming that the ORR of a historical control monotherapy was 10%. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee; PD-L1, programmed death ligand-1; PS, performance status